The cycle for the vanilloid receptor-1 compounds, for example, took three years to complete, while the average cycle for the industry, according to the Centre for Medicine Research, is five years.
Ultimately such compounds could lead to promising new painkillers, but to reach that stage GSK's labs first have to test hundreds of thousands of different compounds with the vanilloid receptor, hunting for the ones that bind.